@bigpharma I think you are talking about the flop of a different drug SR-9001 from Sarepta and the link to that article you mentioned is https://www.********/investing/2021/01/10/heres-why-sarepta-therapeutics-lost-support-on-wal/
@SoT is absolutely correct in alerting us that Sarepta has just received FDA approval on 25.02.2021 for its AMONDYS 45 (Casimersen). Link to the FDA's official announcement is https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0
@bigpharma I think you are talking about the flop of a different...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.8¢ |
Change
-0.003(1.47%) |
Mkt cap ! $781.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $48.06K | 283.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 288373 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 189380 | 7 |
View Market Depth
| Last trade - 10.40am 08/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |